

A

01/05/98

15185 U.S. PTO

Please type a plus sign (+) inside this box → ☐

PTO/SB/05 (12/97) (modified)  
Approved for use through 09/30/00. OMB 0851-0032  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

**UTILITY  
PATENT APPLICATION  
TRANSMITTAL**

Only for new nonprovisional applications under 37 CFR 1.53(b)

Attorney Docket No.	261922003302	Total Pages	* 45
First Named Inventor or Application Identifier			
Albert J.J. van Ooyen et al.			
Express Mail Label No.	EH493640852US		

**CERTIFICATE OF MAILING BY "EXPRESS MAIL"**

Express Mail Label No.: EH493640852US

Date of Deposit: 5 January 1998

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

Kristy N. Canales  
Kristy N. Canales

**APPLICATION ELEMENTS**

See MPEP chapter 600 concerning utility patent application contents

**ADDRESS TO:**

Assistant Commissioner for Patents  
Box Patent Application  
Washington, DC 20231

1. ☒ Fee Transmittal Form  
(Submit an original, and a duplicate for fee processing)
2. ☒ Specification [Total Pages 34]  
(preferred arrangement set forth below)
  - Descriptive title of the Invention
  - Cross References to Related Applications
  - Statement Regarding Fed sponsored R & D
  - Reference to Microfiche Appendix
  - Background of the Invention
  - Brief Summary of the Invention
  - Brief Description of the Drawings (if filed)
  - Detailed Description
  - Claim(s)
  - Abstract of the Disclosure
3. ☒ Drawing(s) (35 USC 113) [Total Sheets 7]
4. Oath or Declaration [Total Pages 4\*]
  - a. ☐ Newly executed (original or copy)
  - b. ☒ Copy from a prior application (37 CFR 1.63(d)  
(for continuation/divisional with Box 17 completed)  
[Note Box 5 below]
  - i. ☐ DELETION OF INVENTOR(S)  
Signed statement attached deleting inventor(s) named in  
the prior application, see 37 CFR 1.63(d)(2) and 1.33(b)
5. ☒ Incorporation By Reference (useable if Box 4b is checked)  
The entire disclosure of the prior application, from which a copy of the  
oath or declaration is supplied under Box 4b, is considered as being  
part of the disclosure of the accompanying application and is hereby  
incorporated by reference therein.

6. ☐ Microfiche Computer Program (Appendix)
7. Nucleotide and/or Amino Acid Sequence Submission  
(if applicable, all necessary)
  - a. ☐ Computer Readable Copy
  - b. ☐ Paper Copy (identical to computer copy)
  - c. ☐ Statement verifying identity of above copies

**ACCOMPANYING APPLICATION PARTS**

8. ☐ Assignment Papers (cover sheet & document(s))
9. ☐ 37 CFR 3.73(b) Statement ☐ Power of Attorney  
(when there is an assignee)
10. ☐ English Translation Document (if applicable)
11. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
12. ☒ Preliminary Amendment
13. ☒ Return Receipt Postcard (MPEP 503)  
(Should be specifically itemized)
14. ☐ Small Entity ☐ Statement filed in prior application,  
Statement(s) Status still proper and desired
15. ☐ Certified Copy of Priority Document(s)  
(if foreign priority is claimed)
16. ☐

17. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:

☒ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No: 08/253,575 FILED 3 June 1994

050033047 010598



- ☒ If a paper is untimely filed in the above-referenced application by applicant or his/her representative, the Assistant Commissioner is hereby petitioned under 37 C.F.R. § 1.136(a) for the minimum extension of time required to make said paper timely. In the event a petition for extension of time is made under the provisions of this paragraph, the Assistant Commissioner is hereby requested to charge any fee required under 37 C.F.R. § 1.17(a)-(d) to **Deposit Account No. 03-1952**. However, the Assistant Commissioner is **NOT** authorized to charge the cost of the issue fee to the Deposit Account.

The filing fee has been calculated as follows:

FOR	NUMBER FILED	NUMBER EXTRA	RATE	CALCULATIONS
TOTAL CLAIMS	43- 20 =	23	x \$22.00	\$506.00
INDEPENDENT CLAIMS	3- 3 =	0	x \$82.00	\$0
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$270.00	\$0
			BASIC FEE	\$790.00
TOTAL OF ABOVE CALCULATIONS =				\$1,296.00
Reduction by 1/2 for filing by small entity (Note 37 C.F.R. §§ 1.9, 1.27, 1.28). If applicable, verified statement must be attached.				\$774.00
Assignment Recording Fee (if enclosed)				\$0
			TOTAL =	\$1,296.00

- ☒ A check in the amount of \$1,296.00 is attached.
- ☐ Charge \$1,296.00 to **Deposit Account No. 03-1952** referencing docket no. 261922003302.

Applicant(s) hereby petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees or to credit any overpayment to **Deposit Account No. 03-1952** referencing docket no. 261922003302. A duplicate copy of this transmittal is enclosed, for that purpose.

Dated: 5 January 1998

Respectfully submitted,

By: Kate H. Murashige  
Kate H. Murashige  
Registration No. 29,959

Morrison & Foerster LLP  
2000 Pennsylvania Avenue, N.W.  
Washington, D.C. 20006-1888  
Telephone: (202) 887-1533  
Facsimile: (202) 887-0763

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

Express Mail Label No.: EH493640852US

Date of Deposit: 5 January 1998

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

  
Kristy N. Canales

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Albert J.J. VAN OYEN et al.

Serial No.: Continuation of 08/253,575

Filing Date: On Even Date Herewith

For: TRANSGENIC PLANTS HAVING A  
MODIFIED CARBOHYDRATE  
CONTENT

Examiner: Unassigned

Group Art Unit: Unassigned

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Prior to examination of the above-referenced case, please amend the application as follows:

Please insert, on page 1, after the title: --This application is a continuation of U.S. Serial No. 08/253,575, filed 3 June 1994, which is a continuation of 07/849,422 filed 12 June 1992.--

IN THE CLAIMS

Please amend the claims as follows:

1. (Amended) A method for modifying the carbohydrate composition of a plant or plant organ [characterized by the growing of a] , wherein said method comprises growing a stably transformed transgenic plant containing [an expression cassette which contains a DNA sequence encoding a (primary) enzyme of interest capable of degrading a plant polysaccharide, under conditions conducive whereby said enzyme-encoding DNA sequence is expressed and the carbohydrate composition of said plant or plant organ is modified, with the proviso that if said plant or plant organ is potato, the DNA sequence encoding said (primary) enzyme of interest originates from a microbial source] a recombinant expression construct encoding a microbial glucanase under conditions wherein said glucanase-encoding construct is expressed and the carbohydrate composition of said plant or plant organ is modified.

Please cancel claims 2-18 and add the following new claims:

- 19. The method of claim 1, wherein said glucanase is an exo-glucanase.
20. The method of claim 19, wherein said exo-glucanase is an exo-1,3- $\beta$ -glucanase.
21. The method of claim 19, wherein said exo-glucanase is an exo-1,4- $\alpha$ -D glucanase.
22. The method of claim 21, wherein said exo-1,4- $\alpha$ -D glucanase is an amyloglucosidase.
23. The method of claim 21, wherein said exo-1,4- $\alpha$ -D glucanase is a  $\beta$ -amylase.
24. The method of claim 21, wherein said exo-1,4- $\alpha$ -D glucanase is an  $\alpha$ -glucosidase.

25. The method of claim 21, wherein said exo-1,4- $\alpha$ -D glucanase is an exo-amylase.
26. The method of claim 1, wherein said glucanase is an endo-glucanase.
27. The method of claim 26, wherein said endo-glucanase is an endo-1,3- $\beta$ -glucanase.
28. The method of claim 26, wherein said endo-glucanase is an endo-1,4- $\beta$ -glucanase.
29. A method for modifying the carbohydrate composition of a plant or plant organ, wherein said method comprises growing a stably transformed, transgenic plant containing a recombinant expression construct encoding a microbial xylanase under conditions wherein said xylanase-encoding construct is expressed and the carbohydrate composition of said plant or plant organ is modified.
30. The method of claim 29, wherein said xylanase is an endo-1,4- $\beta$ -xylanase.
31. The method of claim 29, wherein said xylanase is an endo-1,3- $\beta$ -D xylanase.
32. The method of claim 29, wherein said xylanase is a  $\beta$ -D xylosidase.
33. A method for modifying the carbohydrate composition of a plant or plant organ, wherein said method comprises growing a stably transformed, transgenic plant containing a recombinant expression construct encoding a microbial starch debranching enzyme under conditions wherein said starch debranching enzyme-encoding construct is expressed and the carbohydrate composition of said plant or plant organ is modified.

34. The method of claim 33, wherein said starch debranching enzyme is an isoamylase.

35. The method of claim 33, wherein said starch debranching enzyme is a pullulanase.

36. The method of claim 1, wherein said expression cassette contains a regulatory sequence operably linked to and capable of directing tissue-specific expression of said DNA expression construct or vector.

37. The method of claim 29, wherein said expression cassette contains a regulatory sequence operably linked to and capable of directing tissue-specific expression of said DNA expression construct or vector.

38. The method of claim 33, wherein said expression cassette contains a regulatory sequence operably linked to and capable of directing tissue-specific expression of said DNA expression construct or vector.

39. The method of claim 1, wherein said DNA expression cassette or vector encoding the enzyme is fused to a nucleotide sequence encoding a leader sequence that is operably linked to said enzyme, said leader sequence being capable of targeting the enzyme to a cellular compartment or organelle.

40. The method of claim 29, wherein said DNA expression cassette or vector encoding the enzyme is fused to a nucleotide sequence encoding a leader sequence that is operably linked to said enzyme, said leader sequence being capable of targeting the enzyme to a cellular compartment or organelle.

41. The method of claim 33, wherein said DNA expression cassette or vector encoding the enzyme is fused to a nucleotide sequence encoding a leader sequence that is operably linked to said enzyme, said leader sequence being capable of targeting the enzyme to a cellular compartment or organelle.

42. The method of claim 1, wherein said transgenic plant contains at least one expression cassette which contains a nucleotide sequence encoding a second microbial enzyme.

43. The method of claim 29, wherein said transgenic plant contains at least one expression cassette which contains a nucleotide sequence encoding a second microbial enzyme.

44. The method of claim 33, wherein said transgenic plant contains at least one expression cassette which contains a nucleotide sequence encoding a second microbial enzyme.

45. The method of claim 42, wherein the second microbial enzyme is capable of using the degradation products resulting from the action of the first enzyme as a substrate.

46. The method of claim 43, wherein the second microbial enzyme is capable of using the degradation products resulting from the action of the first enzyme as a substrate.

47. The method of claim 44, wherein the second microbial enzyme is capable of using the degradation products resulting from the action of the first enzyme as a substrate.



48. The method of claim 45, wherein the second enzyme is selected from the group consisting of a maltase, an  $\alpha$ -dextrinase, an  $\alpha$ -1,6-glucosidase, a glucose isomerase and an invertase.

49. The method of claim 46, wherein the second enzyme is selected from the group consisting of a maltase, an  $\alpha$ -dextrinase, an  $\alpha$ -1,6-glucosidase, a glucose isomerase and an invertase.

50. The method of claim 47, wherein the second enzyme is selected from the group consisting of a maltase, an  $\alpha$ -dextrinase, an  $\alpha$ -1,6-glucosidase, a glucose isomerase and an invertase.

51. The method of claim 1, further characterized in that said transgenic plant is selected from the group consisting of tomato, potato, corn, cassava, carrot, lettuce, strawberry and tobacco.

52. The method of claim 29, further characterized in that said transgenic plant is selected from the group consisting of tomato, potato, corn, cassava, carrot, lettuce, strawberry and tobacco.

53. The method of claim 33, further characterized in that said transgenic plant is selected from the group consisting of tomato, potato, corn, cassava, carrot, lettuce, strawberry and tobacco.

54. A recombinant DNA expression cassette comprising a regulatory sequence operably linked to a nucleotide sequence encoding a microbial enzyme selected from the group

consisting of glucanase, xylanase and starch debranching enzymes, which regulatory sequence is selected from the group consisting of

- a) a regulatory sequence that directs expression of said enzyme-encoding nucleotide sequence at a selected stage of development or maturity of the transgenic plant or plant organ;
- b) a regulatory sequence comprising a 35S CaMV promoter; and
- c) a regulatory sequence directs tissue-specific expression of said enzyme-encoding nucleotide sequence in a plant.

55. A vector comprising an expression cassette according to claim 54.

56. A stably transformed, transgenic plant, characterized in that said plant contains an expression cassette according to any one of claims 54.

57. A bacterial strain characterized in that said bacterial strain contains a vector according to claim 55.

58. A stably transformed, transgenic plant or plant organ, characterized in that said plant or plant organ contains a modified carbohydrate composition, said plant or plant organ being made by the method of claim 1.

59. A stably transformed, transgenic plant or plant organ, characterized in that said plant or plant organ contains a modified carbohydrate composition, said plant or plant organ being made by the method of claim 29.

60. A stably transformed, transgenic plant or plant organ, characterized in that said plant or plant organ contains a modified carbohydrate composition, said plant or plant organ being made by the method of claim 33.

### REMARKS

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket no. 261922003302. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated: January 5, 1998

By:

Kate H. Murashige  
Kate H. Murashige  
Registration No. 29,959

Morrison & Foerster LLP  
2000 Pennsylvania Avenue, N.W.  
Washington, D.C. 20006-1888  
Telephone: (202) 887-1533  
Facsimile: (202) 887-0763

5     Transgenic Plants Having a Modified Carbohydrate Content

Field of the Invention

          The present invention relates to the development of transgenic plants having a modified carbohydrate composition.

10

Background of the Invention

          It has long been an objective of the agriculture industry to develop crops having a modified carbohydrate composition, thus providing plants or plant organs more suitable for  
15 certain applications. Such modified crops provide plant products having a modified flavor, a higher content of desired saccharides and/or a more desirable texture. These crops may be either consumed directly or used in further processing.

20         In several plant species such as corn (Shannon & Garwood, 1984), pea (Bhattacharyya et al., 1990), potato (Hovenkamp-Hermelink et al., 1987), Arabidopsis (Caspar et al., 1985; Lin et al., 1988a; Lin et al., 1988b) and tobacco (Hanson et al., 1988), mutants with an altered carbohydrate composition  
25 have been found. This phenomenon may be attributable to mutations found mainly in enzymes involved in the regulation of the synthesis of starch. Some of these mutants are already used in the food industry, such as sweet corn (Shannon & Garwood, supra), which may be directly consumed.

30         Mutants altered in starch metabolism may be obtained via classical techniques such as random screening procedures and breeding. However, these methods are laborious and time consuming processes. Moreover, breeding may give rise to the phenotype that is screened for, but may lead to the loss of  
35 other desired characteristics, or the introduction of highly undesired characteristics (such as potatoes having a high alkaloid content). Changing plant characteristics through genetic engineering is a precise and predictable method, the nature of the gene which is spliced into the genome is known  
40 and no undesired genes are integrated simultaneously.

09003047.010598

Finally, modification of a specific characteristic, for instance, the alteration of the level or nature of certain products in the mutant is often difficult or even impossible using classical techniques. As such, genetic modification techniques have opened up new strategies and lead to new products that cannot be obtained by classical techniques.

It would be clearly advantageous to develop sophisticated and predictable methods for obtaining plants having a modified carbohydrate composition, based on genetical engineering techniques.

In U.S. Patent 4,801,540, DNA fragments are disclosed encoding an enzyme capable of hydrolyzing poly (1,4- $\alpha$ -D galacturonide) glycan into galacturonic acid. Expression constructs are provided in which the structural gene encoding this enzyme is linked to modified regulatory regions in order to modulate the expression of the enzyme. The purpose of the invention as disclosed in the publication is to decrease expression levels of the polygalacturonase enzyme in order to inhibit the degradation of polygalacturonic acid and thus control fruit ripening.

In PCT application WO 89/12386, plants and methods are disclosed in which the carbohydrate content is modified through the expression, in planta, of enzymes such as sucrase and levan sucrase. The object of the invention is to increase the concentration of high molecular weight carbohydrate polymers in fruit in order to alter soluble solids and viscosity.

European Patent Application 438,904 describes the modification of plant metabolism (especially in tubers) whereby the level of phosphofructokinase activity is increased, resulting in significantly reduced levels of sucrose and reducing sugars accumulating in the tubers.

PCT application WO 90/12876 describes the regulation of endogenous  $\alpha$ -amylase activity in genetically modified potato plants. The disclosure states that a reduction of potato  $\alpha$ -amylase activity, and thus a reduction of the degradation of starch to reducing sugars is desirable for the production of potato chips as reducing sugars may be subjected to Maillard reactions during the frying of the potatoes which leads to a

00003047-010599

detrimental effect on the flavor and texture of the product. On the other hand, the disclosure states that a higher potato  $\alpha$ -amylase activity, and thus a higher reducing sugar content is desired if the modified potato tubers are to be used for fermentation for the production of spirits.

#### Summary of the Invention

The present invention provides transgenic plants or plant organs which have a modified polysaccharide composition, as well as methods for the production of such plants. This is achieved via the introduction into the plant of a DNA sequence encoding an enzyme which is capable of degrading plant polysaccharides.

The present invention also provides DNA expression constructs and vectors for the transformation of plants. The expression constructs are under the control of regulatory sequences which are capable of directing the expression of the selected polysaccharide modification enzymes. These regulatory sequences may also include sequences capable of directing the expression of the chosen enzymes at a desired developmental stage of the plant or plant organ and/or tissue specifically.

Furthermore, depending on the products desired in planta, one or more additional expression constructs may be introduced into the plant. These additional expression constructs contain DNA sequences encoding secondary enzymes which convert the degradation products resulting from the first enzymatic reaction to the desired oligo- or monosaccharides.

The transgenic plants provided by the present invention find applications as new products with a modified taste, solids content and/or more desirable texture.

#### Brief Description of the Figures

- Figure 1. Binary vector pMOG23.  
Figure 2. Genomic sequence of the  $\alpha$ -amylase gene of Bacillus licheniformis as present in the vector pPROM54.  
Figure 3. Synthetic oligonucleotide duplexes used for the

various constructions.

Figure 4. Binary plasmid pMOG228, which comprises binary vector pMOG23 containing the genomic DNA sequence encoding mature  $\alpha$ -amylase from Bacillus licheniformis preceded by a methionine translation initiation codon.

Figure 5. Binary plasmid pMOG450, which comprises binary vector pMOG23 containing the genomic DNA sequence encoding mature  $\alpha$ -amylase from Bacillus licheniformis, preceded by a methionine translation initiation codon and under the control of the class-I patatin promoter from potato.

Figure 6. Binary plasmid pMOG437, which comprises binary vector pMOG23 containing DNA sequences encoding mature  $\alpha$ -amylase from Bacillus licheniformis and mature glucoamylase from Aspergillus niger, both preceded by a methionine translation initiation codon and both under the control of a class-I patatin promoter from potato.

#### Detailed Description of the Preferred Embodiments

The present invention provides transgenic plants or plant organs which have a modified polysaccharide composition and overcomes the disadvantages encountered in classical plant breeding techniques by the stable introduction into the plants of DNA sequences encoding certain enzymes which are capable of polysaccharide degradation.

It was found unexpectedly that the transformation of tobacco with a bacterial  $\alpha$ -amylase gene (lacking a secretory signal sequence) resulted in the accumulation of maltodextrins such as maltose and maltotriose, which is indicative of  $\alpha$ -amylase activity. This finding demonstrates that it is possible to modify polysaccharide composition in planta by the introduction and translation of a gene encoding a polysaccharide degrading enzyme.

The observed degradation of starch by the introduction of the  $\alpha$ -amylase enzyme is very surprising since in plant cells, the entire process of starch synthesis occurs in the specific

organelles (chloroplasts, amyloplasts and the like) where starch is stored, whereas the expressed  $\alpha$ -amylase is expected to be present in the cytoplasm since no sequences were present to direct the  $\alpha$ -amylase to these organelles. Certain  
5 starch degrading enzymes are endogenous to the cytoplasm of plant leaf cells. However, their function in the cytoplasm has never been conclusively explained and has never been correlated with the degradation of starch, in planta, because of the compartmental division of the two entities (Caspar et  
10 al., 1989; Lin et al., 1988 a,b and c; Okita et al., 1979).

According to the present invention, the extent to which the taste and/or texture of the plants is modified may be regulated using a variety of means including the choice of the saccharide modifying enzyme or enzymes, the choice of the  
15 regulatory regions of the DNA construct designed for the expression of the enzyme of interest and the targeting of the expressed enzyme to a pre-determined intracellular locus.

The choice of the enzyme or enzymes of interest is clearly of paramount importance in obtaining the desired  
20 final product. Should more than one enzyme of interest be expressed in a plant, the ratios of the respective enzymes may be chosen in order to obtain the optimal effect (e.g. the desired sweetness).

The regulation of the expression of the enzyme(s) of  
25 interest with respect to expression level and spatial (tissue/organ specific) and/or developmental regulation of expression is also a means of obtaining an optimal product. For example, the type and strength of the promoter with respect to the timing and/or location of the expression of  
30 the enzyme(s) of interest will provide optimal levels of the enzyme(s) of interest in the desired locus of the transformed plant.

Finally, the locus (e.g. cellular compartment or organelle) to which the expressed enzyme may be targeted can  
35 be chosen so that an optimal effect, such as better access to the substrate, is obtained.

Variations in expression levels are sometimes observed as a result of varying copy number and/or site of integration of the transforming DNA. This natural variation may be used to

09003047.010598



select those individual plants from the pool of transgenic plants which have the desired characteristics in terms of sweetness, texture and the like. These individual plants can be used for multiplication and/or breeding with other varieties.

Combinations of the above measures may also be used to obtain the desired effect. Methods of obtaining optimal products may be determined by the skilled artisan using the teaching found below.

According to the present invention, (primary) enzymes of interest to be expressed in plants include any enzymes or combination of enzymes which are capable of degrading plant polysaccharides. Especially preferred are enzymes encoded by DNA sequences which are of microbial origin. If necessary, the coding and/or regulatory sequences may be modified to achieve cytoplasmic or organellar expression, tissue specificity or expression at a desired maturity stage of the plant or plant organ. Furthermore, codons may be modified to improve expression of the gene in the selected plant host.

Enzymes of interest capable of use in conjunction with the present invention include:

- a) starch degrading enzymes such as 1)  $\alpha$ -amylases (EC 3.2.1.1); 2)  $\alpha$ -D glucanases such as amyloglucosidases (EC 3.2.1.3),  $\beta$ -amylases (EC 3.2.1.2),  $\alpha$ -glucosidases (EC 3.2.1.20), and other  $\alpha$ -amylases; and 3) starch debranching enzymes, such as isoamylase (EC 3.2.1.68), pullulanase (EC 3.2.1.41), and the like;
- b) cellulases such as  $\alpha$ -D-cellobiohydrolase (EC 3.2.1.91),  $\alpha$ -D-glucanase (EC 3.2.1.39),  $\beta$ -glucosidase (EC 3.2.1.21) and the like;
- c) endoglucanases such as  $\alpha$ -D-glucanase (EC 3.2.1.6) and  $\alpha$ -D-glucanase (EC 3.2.1.4) and the like;
- d) L-arabinases, such as  $\alpha$ -L-arabinase (EC 3.2.1.99),  $\alpha$ -arabinosidases (EC 3.2.1.55) and the like;
- e) galactanases such as  $\alpha$ -D-galactanase (EC 3.2.1.89),  $\alpha$ -D-galactanase (EC 3.2.1.90),  $\alpha$ -galactosidase (EC 3.2.1.22),  $\beta$ -galactosidase (EC 3.2.1.23) and the like;
- f) mannanases, such as  $\alpha$ -D-mannanase (EC 3.2.1.78),

$\beta$ -mannosidase (EC 3.2.1.25),  $\alpha$ -mannosidase (EC 3.2.1.24) and the like;

g) xylanases, such as endo-1,4- $\beta$ -xylanase (EC 3.2.1.8),  $\beta$ -D-xylosidase (EC 3.2.1.37), 1,3- $\beta$ -D-xylanase, and the like;

5 h) other enzymes such as  $\alpha$ -L-fucosidase (EC 3.2.1.51),  $\alpha$ -L-rhamnosidase (EC 3.2.1.40), levanase (EC 3.2.1.65), inulanase (EC 3.2.1.7), and the like.

Optionally, in a further embodiment, the present invention also contemplates the introduction to the target  
10 (host) plant of one or more additional DNA constructs encoding secondary enzymes of interest which are capable of further modifying the polysaccharide degradation products (obtained from the action of the primary polysaccharide degrading enzyme(s)) to desired saccharide subunits.  
15 Especially preferred secondary enzymes are enzymes encoded by DNA sequences which are of microbial origin.

To illustrate, secondary enzymes of particular interest, which are capable of further degrading the maltose, maltotriose and  $\alpha$ -dextrins obtained from the first  
20 degradation of starch, include inter alia, maltases,  $\alpha$ -dextrinase,  $\alpha$ -1,6-glucosidases, and the like. The action of these enzymes result in the formation of glucose.

In yet a further embodiment of the present invention, if desired, one or more further secondary enzymes, which are  
25 capable of modifying monosaccharides, may be expressed in the same plant. Such enzymes include but are not limited to glucose isomerase, invertase, and the like.

The source from which DNA sequences encoding these enzymes of interest may be obtained is not relevant, provided  
30 the enzyme is active in the environment in which the enzyme is expressed or in which the expressed enzyme is targeted. The choice of both the primary (plant polysaccharide degrading) and, if desired, secondary enzymes of interest may depend on the substrate specificity and/or the desired  
35 saccharide end-product.

The enzymes of interest may be expressed constitutively in the transgenic plants during all stages of development. Depending on the use of the plant or plant organs, the enzymes may be expressed in a stage-specific manner, for

instance during tuber formation or fruit development. Furthermore, depending on the use, the enzymes may be expressed tissue-specifically, for instance in plant organs such as fruit, tubers, leaves or seeds.

5 Plant polysaccharides, as defined within the context of the present invention are intended to consist of polyhydroxy aldehydes or ketones, consisting of more than six covalently-linked monosaccharides, which are normally found in plants prior to the action of the enzyme or enzymes of interest  
10 according to the present invention. Such polysaccharides are typically polymers of D-arabinose, D-fructose, D- and L-galactose, D-glucose, and D-xylose and mannose.

Saccharide subunits, the desired end-products of the present invention, are defined as saccharides having a  
15 shorter chain length than the original polysaccharide, including monosaccharides, which are obtained via the action of one or more enzymes of interest on the plant polysaccharides.

Transgenic plants, as defined in the context of the  
20 present invention include plants (as well as parts and cells of said plants) and their progeny which have been genetically modified using recombinant DNA techniques to cause or enhance production of at least one enzyme of interest in the desired plant or plant organ.

25 Plants capable of being used in conjunction with the present invention include, but are not limited to crops producing edible flowers such as cauliflower (Brassica oleracea), artichoke (Cynara scolymus), fruits such as apple (Malus, e.g. domesticus), banana (Musa, e.g. acuminata),  
30 berries (such as the currant, Ribes, e.g. rubrum), cherries (such as the sweet cherry, Prunus, e.g. avium), cucumber (Cucumis, e.g. sativus), grape (Vitis, e.g. vinifera), lemon (Citrus limon), melon (Cucumis melo), nuts (such as the walnut, Juglans, e.g. regia; peanut, Arachis hypogaeae),  
35 orange (Citrus, e.g. maxima), peach (Prunus, e.g. persica), pear (Pyrus, e.g. communis), pepper (Solanum, e.g. capsicum), plum (Prunus, e.g. domestica), strawberry (Fragaria, e.g. moschata), tomato (Lycopersicon, e.g. esculentum), leafs, such as alfalfa (Medicago, e.g. sativa), cabbages (such as

Brassica oleracea), endive (Cichoreum, e.g. endivia), leek (Allium, e.g. porrum), lettuce (Lactuca, e.g. sativa), spinach (Spinacia e.g. oleraceae), tobacco (Nicotiana, e.g. tabacum), roots, such as arrowroot (Maranta, e.g. arundinacea), beet (Beta, e.g. vulgaris), carrot (Daucus, e.g. carota), cassava (Manihot, e.g. esculenta), turnip (Brassica, e.g. rapa), radish (Raphanus, e.g. sativus), yam (Dioscorea, e.g. esculenta), sweet potato (Ipomoea batatas) and seeds, such as bean (Phaseolus, e.g. vulgaris), pea (Pisum, e.g. sativum), soybean (Glycin, e.g. max), wheat (Triticum, e.g. aestivum), barley (Hordeum, e.g. vulgare), corn (Zea, e.g. mays), rice (Oryza, e.g. sativa), tubers, such as kohlrabi (Brassica, e.g. oleraceae), potato (Solanum, e.g. tuberosum), and the like.

The choice of the plant species is determined by the intended use of the plant or parts thereof and the amenability of the plant species to transformation.

The expression of recombinant genes in plants involves such details as transcription of the gene by plant polymerases, translation of mRNA, etc., which are known to persons skilled in the art of recombinant DNA techniques. Only details relevant for the proper understanding of this invention are discussed below.

Regulatory sequences which are known or are found to cause expression of a gene encoding an enzyme of interest in planta may be used in the present invention. The choice of the regulatory sequences used depends on the target crop and/or target organ of interest. Such regulatory sequences may be obtained from plants or plant viruses, or may be chemically synthesized. Such regulatory sequences are promoters active in directing transcription in plants, either constitutively or developmental stage- and/or tissue-specifically, depending on the use of the plant or parts thereof. These promoters include, but are not limited to promoters showing constitutive expression, such as the 35S promoter of Cauliflower Mosaic Virus (CaMV) (Guilley et al., 1982), those for leaf-specific expression, such as the promoter of the ribulose biphosphate carboxylase small subunit gene (Coruzzi et al., 1984), those for root-specific

expression, such as the promoter from the glutamine synthase gene (Tingey et al., 1987), those for seed-specific expression, such as the cruciferin A promoter from Brassica napus (Ryan et al., 1989), those for tuber-specific  
5 expression, such as the class-I patatin promoter from potato (Rocha-Sosa et al., 1989; Wenzler et al., 1989) or those for fruit-specific expression, such as the polygalacturonase (PG) promoter from tomato (Bird et al., 1988).

Other regulatory sequences such as terminator sequences  
10 and polyadenylation signals include any such sequence functioning as such in plants, the choice of which is within the level of the skilled artisan. An example of such sequences is the 3' flanking region of the nopaline synthase (nos) gene of Agrobacterium tumefaciens (Bevan, 1984).

15 The regulatory sequences may also include enhancer sequences, such as found in the 35S promoter of CaMV, and mRNA stabilizing sequences such as the leader sequence of Alfalfa Mosaic Virus (AlMV) RNA4 (Brederode et al., 1980) or any other sequences functioning in a like manner.

20 In one embodiment of the present invention, if simple expression of an enzyme of interest into the cytoplasm of the plant cell should be desired, the expressed enzyme should not contain a secretory signal peptide or any other targeting sequence.

25 In another embodiment of the present invention, the DNA construct encoding a selected enzyme of interest according to the present invention may optionally be provided with leader sequences capable of targeting the expressed enzyme to a pre-determined locus in order to have better access of the enzyme  
30 to its substrate. Targeting sequences which may be operably coupled to the enzyme of interest in order to achieve this function have been described in the literature (Smeekens et al., 1990; van den Broeck et al., 1985; Schreier et al., 1985). For example, to obtain expression in chloroplasts and  
35 mitochondria, the expressed enzyme should contain a specific so-called transit peptide for import into these organelles (Smeekens et al., 1990). If the activity of the enzyme is desired in the vacuoles, a secretory signal sequence must be present, as well as a specific targeting sequence that

directs the enzyme to these vacuoles (Tague et al., 1988). This may also lead to the targeting of the enzyme to seeds.

All parts of the relevant DNA constructs (promoters, regulatory-, stabilizing-, targeting- or termination sequences) of the present invention may be modified, if desired, to affect their control characteristics using methods known to those skilled in the art.

Several techniques are available for the introduction of the expression construct containing a DNA sequence encoding an enzyme of interest into the target plants. Such techniques include but are not limited to transformation of protoplasts using the calcium/polyethylene glycol method, electroporation and microinjection or (coated) particle bombardment (Potrykus, 1990).

In addition to these so-called direct DNA transformation methods, transformation systems involving vectors are widely available, such as viral vectors (e.g. from the Cauliflower Mosaic Virus (CaMV), Fraley et al., 1986) and bacterial vectors (e.g. from the genus Agrobacterium) (Potrykus, 1990). After selection and/or screening, the protoplasts, cells or plant parts that have been transformed can be regenerated into whole plants, using methods known in the art (Horsch, et al., 1985). The choice of the transformation and/or regeneration techniques is not critical for this invention.

For dicots, an embodiment of the present invention employs the principle of the binary vector system (Hoekema et al., 1983; Schilperoort et al., 1984) in which Agrobacterium strains are used which contain a vir plasmid with the virulence genes and a compatible plasmid containing the gene construct to be transferred. This vector can replicate in both E.coli and in Agrobacterium, and is derived from the binary vector Bin19 (Bevan, 1984) which is altered in details that are not relevant for this invention. The binary vectors as used in this example contain between the left- and right-border sequences of the T-DNA, an identical NPTII-gene coding for kanamycin resistance (Bevan, 1984) and a multiple cloning site to clone in the required gene constructs.

The transformation and regeneration of monocotyledonous crops is not a standard procedure. However, recent scientific

progress shows that in principle monocots are amenable to transformation and that fertile transgenic plants can be regenerated from transformed cells. The development of reproducible tissue culture systems for these crops, together with the powerful methods for introduction of genetic material into plant cells has facilitated transformation. Presently the methods of choice for transformation of monocots are microprojectile bombardment of explants or suspension cells, and direct DNA uptake or electroporation of protoplasts. For example, transgenic rice plants have been successfully obtained using the bacterial hph gene, encoding hygromycin resistance, as a selection marker. The gene was introduced by electroporation (Shimamoto et al., 1989). Transgenic maize plants have been obtained by introducing the bar gene from Streptomyces hygroscopicus, which encodes phosphinothricin acetyltransferase (an enzyme which inactivates the herbicide phosphinothricin), into embryogenic cells of a maize suspension culture by microparticle bombardment (Gordon-Kamm et al., 1990). The introduction of genetic material into aleurone protoplasts of other monocot crops such as wheat and barley has been reported (Lee et al., 1989). The stable transformation of wheat cell suspension cultures via microprojectile bombardment has recently been described (Vasil et al., 1991). Wheat plants have been regenerated from embryogenic suspension culture by selecting only the aged compact and nodular embryogenic callus tissues for the establishment of the embryogenic suspension cultures (Vasil et al., 1990). The combination of regeneration techniques with transformation systems for these crops enables the application of the present invention to monocots. These methods may also be applied for the transformation and regeneration of dicots.

If desired, a number of methods may be used to obtain transgenic plants in which more than one enzyme of interest is expressed. These include but are not limited to:

- a. Cross-fertilization of transgenic plants each expressing a different enzyme of interest.
- b. Plant transformation with a DNA fragment or plasmid that contains multiple genes, each encoding an enzyme of

interest, each containing its own necessary regulatory sequences.

- c. Plant transformation with different DNA fragments or plasmids simultaneously, each containing a gene for an enzyme of interest, using the necessary regulatory sequences.
- d. Successive transformations of plants, each time using a DNA fragment or plasmid encoding a different enzyme of interest under the control of the necessary regulatory sequences.
- e. A combination of the methods mentioned above.

The choice of the above methods is not critical with respect to the objective of this invention.

In one embodiment of the present invention, an  $\alpha$ -amylase is constitutively expressed intracellularly in tobacco and tomato plants, resulting in the degradation of starch in these plants to lower molecular weight saccharides. A genomic DNA fragment encoding mature  $\alpha$ -amylase from Bacillus licheniformis, i.e. encoding the  $\alpha$ -amylase without the signal peptide sequence, is placed under the control of the CaMV 35S promoter and enhancer sequences. The mRNA stabilizing leader sequence of RNA4 from ALMV is included, as well as the terminator and polyadenylation signal sequences of the nopaline synthase (nos) gene of Agrobacterium tumefaciens. The construct is thereafter subcloned into a binary vector such as pMOG23 (deposited at the Centraal Bureau voor Schimmelcultures, Baarn, the Netherlands on January 29, 1990 under accession number CBS 102.90). This vector is introduced into Agrobacterium tumefaciens which contains a disarmed Ti-plasmid. Bacterial cells containing this construct are co-cultivated with tissues from the target plants, and transformed plant cells are selected on nutrient media containing antibiotics and induced to regenerate into differentiated plants on such media. The resulting plants contain the stably integrated gene and express the  $\alpha$ -amylase intracellularly.

The  $\alpha$ -amylase enzyme activity of the transgenic plants may be tested with direct enzyme assays using colorimetric techniques or gel assays. The assay of choice is not critical

09003047.010593



to the present invention. The protein is detectable on Western blots with antibodies raised against  $\alpha$ -amylase from Bacillus licheniformis.

The plants may be qualitatively assayed for starch content either by staining for starch with iodine. Plants may be quantitatively assayed for the presence of starch degradation products by using techniques as NMR and HPLC. Other methods may also be used. The choice of the method is not critical to the present invention.

10 In another preferred embodiment, both an  $\alpha$ -amylase and a glucoamylase are expressed in potatoes. The enzymes are expressed only in the tubers of the plants. The result is the degradation of starch in tubers by both enzymes to lower molecular weight saccharides. A genomic DNA fragment encoding  
15 mature  $\alpha$ -amylase from Bacillus licheniformis and a cDNA fragment encoding mature glucoamylase from Aspergillus niger are each placed under the control of the tuber-specific promoter from a class-I patatin gene from potato. Both constructs also include the terminator and polyadenylation  
20 signal sequences of the nopaline synthase (nos) gene of Agrobacterium tumefaciens. Both constructs are thereafter subcloned together into the binary vector pMOG23. This vector is introduced into Agrobacterium tumefaciens, which contains a disarmed Ti plasmid. Bacterial cells containing this  
25 construct are cocultivated with tissues from potato plants and transformed plant cells are selected on nutrient media containing antibiotics, and induced to regenerate into differentiated plants on such media. The resulting plants contain the stably integrated genes. Both  $\alpha$ -amylase and  
30 glucoamylase are expressed only in the tubers of the transformed potatoes. Both enzymes are expressed intracellularly.

The  $\alpha$ -amylase and glucoamylase enzyme activities in the transgenic tubers can be tested with various assays. For  
35 example, glucoamylase activity may be determined by an assay measuring p-nitrophenol released from p-nitrophenol- $\alpha$ -D-glucopyranoside by the glucoamylase. Alpha-amylase activity may be measured as described above and in the examples provided below. The presence of both enzymes may be

demonstrated by immunoblotting, for example. The choice of assays is not relevant to the present invention.

The transgenic potato tubers may be assayed for their carbohydrate composition by using techniques for the  
5 detection of sugars such as HPLC and NMR. Other methods may also be used. The choice of the method is not critical to the present invention.

Transgenic plants or plant organs (such as flowers, fruits, leaves, roots, tubers) having a higher content of  
10 polysaccharide degradation products and consequently a modified flavor and/or a desired texture, may be used as a new product either as such or in a form obtained after non-fermentative processing which retains the distinctive  
15 saccharides. Examples of such uses are the production of baby foods, juices, sauces, pastes, concentrates, sweeteners, jams, jellies, syrups, and animal feeds. Grains having an altered carbohydrate composition may be used in the  
20 productions of baked products, for example, which have a modified taste. Tobaccos having an altered carbohydrate composition exhibit a modified taste and aroma.

Alternatively, the polysaccharide degradation products may be extracted from the plant or plant organs and used as such, for instance as a sweetener, or in various processes.

25 The following examples are provided so as to give those of ordinary skill in the art a complete disclosure and description of how to make and use the invention and are not intended to limit the scope of what the inventors regard as their invention. Efforts have been made to ensure accuracy  
30 with respect to numbers used (e.g., amounts, temperature, pH, etc.) but some experimental errors and deviation should be accounted for. Unless indicated otherwise, temperature is in degrees Centigrade and pressure is at or near atmospheric.

35

#### Example 1

##### Construction of the binary vector pMOG23.

The binary vector pMOG23 (deposited at the Centraal Bureau voor Schimmelcultures, Baarn, The Netherlands, on January 29, 1990, under accession number CBS 102.90; shown in

09003047 010598

Figure 1) is a derivative of vector Bin19 (Bevan, 1984). First, the positions of the left border (LB) and the right border (RB) were interchanged with reference to the neomycin phosphotransferase gene II (NPTII gene). Secondly, the orientation of the NPTII gene was reversed giving transcription in the direction of LB. Finally, the polylinker of Bin19 was replaced by a polylinker having the following restriction enzyme recognition sites: EcoRI, KpnI, SmaI, BamHI, XbaI, SacI, XhoI, and HindIII.

10

### Example 2

#### Cloning of the $\alpha$ -amylase gene of *Bacillus licheniformis*

All transformations in this example were performed in *E. coli* strain DH5 $\alpha$ .

15

#### a. Tailoring of the $\alpha$ -amylase gene of *Bacillus licheniformis*

The  $\alpha$ -amylase gene (Figure 2) from *Bacillus licheniformis* is present in the *Bacillus* vector pPROM54, which is described in European Patent Application 224,294, the disclosure of which is hereby incorporated by reference. The plasmid pPROM54 has been deposited at the Centraal Bureau voor Schimmelcultures, Baarn, The Netherlands on November 5, 1985, under accession number CBS 696.85.

The plasmid pPROM54 was digested with XbaI and BclI. The XbaI/BclI fragment was cloned in plasmid pUC18 digested with XbaI and BamHI, resulting in plasmid pMOG318. A SalI/BamHI fragment was synthesized with pMOG318 as a template with PCR technology, creating the BamHI site by use of a mismatch primer (the position of the created BamHI site is indicated in Figure 2). The SalI/BamHI PCR fragment was cloned in plasmid pIC-19R (Marsh *et al.*, 1984) digested with SalI and BamHI, resulting in plasmid pMOG319. The SalI fragment from pMOG318 (the second SalI site is present in pUC18), containing the 5' end of the  $\alpha$ -amylase gene, was cloned in pMOG319 digested with SalI. This resulted in plasmid pMOG320 which contains the entire  $\alpha$ -amylase gene.

#### b. Construction of vector pMOG18.

The expression cassette of pROKI (Baulcombe *et al.*, 1986)

09003047-0105 99

was cloned as an EcoRI/HindIII fragment into pUC18. This cassette contains the 800 bp Cauliflower Mosaic Virus (CaMV) 35S promoter fragment on an EcoRI/BamHI fragment and the nopaline synthase (nos) transcription terminator of Agrobacterium tumefaciens on a BamHI/HindIII fragment. The promoter fragment consists of the sequence from -800 to +1 (both inclusive) of the CaMV promoter. Position +1 is the transcription initiation site (Guilley *et al.*, 1982). The sequence upstream of the NcoI site at position -512 was deleted and this site was changed into an EcoRI site. This was achieved by cutting the expression cassette present in pUC18 with NcoI, filling in the single-stranded ends with Klenow polymerase and ligation of an EcoRI linker.

The resulting plasmid was cut with EcoRI, resulting in the deletion of the EcoRI fragment carrying the sequences of the CaMV 35S promoter upstream of the original NcoI site. The BamHI/HindIII fragment, containing the nos terminator was replaced by a synthetic DNA fragment (Oligonucleotide duplex A, Figure 3) containing the leader sequence of RNA4 of Alfalfa Mosaic Virus (AlMV) (Brederode *et al.*, 1980). This was done by cleavage with BamHI, followed by cleavage with HindIII and ligation of the synthetic DNA fragment. The BamHI site and three upstream nucleotides were deleted by site-directed mutagenesis.

In the resulting plasmid, the BamHI/HindIII fragment containing the nos terminator was reintroduced. The gene encoding beta-glucuronidase (originating from plasmid pRAJ 275; Jefferson, 1987) was ligated in as an NcoI/BamHI fragment, resulting in plasmid pMOG14.

It is known that duplication of the sequence between -343 and -90 increases the activity of the CaMV 35S promoter (Kay *et al.*, 1987). To obtain a promoter fragment with a double, so-called enhancer sequence, the enhancer fragment from plasmid pMOG14 was isolated as an AccI/EcoRI fragment and subsequently blunt-ended with Klenow polymerase. The thus-obtained fragment was introduced in pMOG14 cut with EcoRI and blunt-ended, such that the border between the blunt-ended EcoRI and AccI sites generated a new EcoRI site. The resulting plasmid pMOG18 contains the 35S CaMV promoter with

a double enhancer sequence, the leader sequence of RNA4 from AlMV and the nos terminator in an expression cassette still present as an EcoRI/HindIII fragment.

5 c. Cloning of the  $\alpha$ -amylase gene from *Bacillus licheniformis* in the binary vector.

Plasmid pMOG320 was digested with HgaI and BamHI. The HgaI/BamHI fragment was cloned together with the synthetic oligonucleotide duplex B (Figure 3) into pMOG18 digested with  
10 NotI and BamHI, resulting in plasmid pMOG322. The  $\beta$ -glucuronidase gene was thus replaced by the coding sequence for the mature  $\alpha$ -amylase of *Bacillus licheniformis* preceded by the ATG triplet encoding the methionine translation initiation codon. Plasmid pMOG18 contains the 35S promoter  
15 and enhancer of Cauliflower mosaic virus (CaMV), the nopaline synthase (nos) terminator from *Agrobacterium tumefaciens* and the RNA4 leader sequence of Alfalfa mosaic virus (AlMV). The resulting construct does not contain coding information for a signal peptide. The entire construct was spliced out with  
20 EcoRI and HindIII and transferred into the binary vector pMOG23 digested with EcoRI and HindIII. The resulting plasmid has been designated pMOG228 (Figure 4).

The chimeric  $\alpha$ -amylase gene on the binary plasmid pMOG228 was mobilized, in a triparental mating with the *E.coli* strain  
25 HB101 containing plasmid pRK2013 (Ditta et al., 1980), into *Agrobacterium* strain LBA4404, which contains a plasmid having the virulence genes necessary for T-DNA transfer to the plant (Hoekema et al., 1983).

30

Example 3

Transformation of tobacco

Tobacco (*Nicotiana tabacum* cv. Petit Havanna SR 1) was transformed by co-cultivation of plant leaf disks (Horsch et al., 1985) with *Agrobacterium tumefaciens*, containing the  
35 binary vector pMOG228 with the  $\alpha$ -amylase gene. Transgenic plants were selected on kanamycin resistance. The transgenic plants were assayed for activity of the enzyme of interest. Plants expressing the  $\alpha$ -amylase gene were analyzed more thoroughly and used in further experiments.

Leaf discs of about 5 x 5 mm were cut from leaves of axenically grown plants of Nicotiana tabacum cv. Petit Havanna SR1. The discs were floated for 20 minutes in MS-medium (Murashige & Skoog, 1962) containing 30 g/L sucrose with 1% (v/v) of a culture of Agrobacterium tumefaciens LBA4404 (pMOG228) ( $10^9$  cells/ml). Subsequently, the discs were briefly dried on filter paper and transferred to plates containing solid medium consisting of MS-medium, containing 30 g/L sucrose, 7 g/L agar, 1 mg/L kinetin and 0.03 mg/L naphthyl acetic acid (NAA). Two days later, the discs were transferred to plates containing the same medium plus 500 mg/L carbenicillin. After one week, the discs were again transferred to plates containing the same medium, this time with about 50 mg/L kanamycin to select for transgenic shoots. Discs were transferred to fresh plates with three week intervals. Developing shoots were excised and transferred to pots containing solid medium consisting of MS-medium, containing 30 g/L sucrose, 100 mg/L kanamycin and 100 mg/L cefotaxime for root development. After roots have developed, the plants were transferred to the soil. The plants were tested for expression of the gene of interest.

#### Example 4

##### Alpha-amylase expression in transgenic tobacco plants

Alpha-amylase activity was determined by the method described by Saito (1973) at 56 °C. Units are defined in this case as the amount of enzyme giving a reduction of the absorbance at 690 nm by 10% in 10 minutes. Specific activity for the Bacillus licheniformis  $\alpha$ -amylase was  $8.7 \times 10^5$  U/mg protein. The tip of one of the top leaflets (about 100 mg) was cut off and homogenized in 100  $\mu$ l  $\alpha$ -amylase assay buffer (Saito, 1973). The homogenate was spun down for 10 minutes in an Eppendorf centrifuge. The supernatant was collected and assayed for protein and  $\alpha$ -amylase content. Control plants had levels of activity at or below the detection limit.

In the 62 transgenic plants obtained, the measured expression levels, as determined by the method of Saito (1973) varied between 0 and 3.29 U/ $\mu$ g protein. Based on the specific activity of the enzyme, these levels corresponded to

0 - 0.38 % of the total amount of soluble protein. The average was 0.11 % of the total amount of soluble protein. The protein was clearly present intracellularly, since no significant amount of  $\alpha$ -amylase activity was detected in the extracellular fluid that was isolated by vacuum filtration of the leaves with buffer, followed by collection of the fluid by centrifugation (Sijmons *et al.*, 1990). These results were confirmed with immunological detection of the Bacillus licheniformis  $\alpha$ -amylase on Western blots, which demonstrated that the protein is indeed the desired  $\alpha$ -amylase. Further confirmation was obtained by running extracts and extracellular fluid on polyacrylamide-SDS gels. After electrophoresis, the gels were incubated in 0.04 M Tris/HCl pH 7.4 for 3 hours with 6 changes of buffer to renature the enzymes. The gels were overlaid with 0.25% potato Lintner starch, 0.75% agar in 0.05 M Tris/HCl pH 7.4 containing 1 mM  $\text{CaCl}_2$ , incubated overnight at 37 °C and subsequently stained with 1mM  $\text{I}_2$ /0.5 M KI in water. Alpha-amylase activity was detected as a clear zone in the overlay (Lacks & Springhorn, 1980). In the transgenic plants, an  $\alpha$ -amylase was detected having an apparent molecular weight of about 55,000 kDa, the same as that of the Bacillus licheniformis  $\alpha$ -amylase.

Tobacco plants expressing  $\alpha$ -amylase were pale light green (chlorotic) and somewhat retarded in growth as compared to control plants.

#### Example 5

##### Carbohydrate analysis of transgenic tobacco plants

Qualitatively the starch content in transgenic tobacco leaves, collected at roughly the half-way point of the photoperiod, was determined by destaining the leaves overnight by shaking in 96% ethanol, followed by staining for starch with 5.7 mM  $\text{I}_2$  and 43.3 mM KI in 0.2 N HCl. Leaves containing starch stained black-blue, while leaves lacking starch stained brownish-yellow (Caspar *et al.*, 1985).

Approximately 2.5 g portions of leaf material (stored in deep-freeze) obtained from control and transformed (good  $\alpha$ -amylase expressors) plants were homogenized in 10 ml water at 4 °C with an ultra-turrax. Microscopic inspection revealed

that no intact cells remained. After removal of the cell fragments by centrifugation, the glucose oligomer content in the green-colored supernatant was determined. The filtered samples were analyzed via HPLC on an Aminex HPX-42A column (300 mm x 7.8 mm, 85 °C) using water as the eluent. The presence of maltose and maltotriose were detected in the samples of the transformed plants and not in the control (untransformed) plants. The results are shown in Table 1, below.

Table 1

Saccharides extracted from tobacco leaves and analyzed on an Aminex HPX-42A-HPLC column

<u>Preparation</u>	<u>Saccharide</u>	<u>mg Saccharide/g wet material</u>
Control	Maltotriose	undetectable
	Maltose	undetectable
Transgenic	Maltotriose	0.34
	Maltose	1.73

Example 6

Cloning of the  $\alpha$ -amylase gene of *Bacillus licheniformis* in a tuber-specific expression construct

All transformations in *E. coli* in this example were performed in strain DH5 $\alpha$ .

To construct an expression cassette for tuber-specific expression, the promoter from a class-I patatin gene of potato (*Solanum tuberosum* cv. Bintje) is synthesized using PCR technology with isolated genomic DNA (Mettler, 1987) as a template. Class-I patatin genes show tuber-specific expression in potato. Both the coding and flanking sequences of several members of the patatin multigene family have been determined (Rocha-Sosa *et al.*, 1989; Bevan *et al.*, 1986; Mignery *et al.*, 1988). Chimeric genes have been reported containing 5' flanking regions of a class-I patatin gene fused to  $\beta$ -glucuronidase, giving rise to tuber-specific expression of  $\beta$ -glucuronidase (Wenzler *et al.*, 1989).

Two oligonucleotides corresponding to the sequence of the PAT21 and B33 genes (Mignery *et al.*, 1989; Bevan *et al.*,



1986), are synthesized, allowing the amplification of the class-I patatin 5' flanking region as a HindIII/NcoI fragment:

5' ATTAAGCTTATGTTGCCATATAGAGTAGT 3'

5 GTAGGATCCATGGTGCAAATGTTCAAAGTGT 3'

The oligonucleotides are designed to contain suitable restriction sites (HindIII and NcoI) at their termini to allow assembly of the expression cassette after digestion of the fragments with the restriction enzymes. A fragment of about 1.3 kb containing a functional class-I patatin promoter fragment was synthesized. After addition of EcoRI synthetic linkers by ligation, the fragment was cloned in pUC18 linearized with EcoRI, resulting in plasmid pMOG546. In a three-way ligation, the HindIII/NcoI-fragment of plasmid pMOG546, together with the NcoI/HindIII fragment of plasmid pMOG322 (see Example 2, encoding mature  $\alpha$ -amylase of Bacillus licheniformis preceded by an ATG translation initiation codon and followed by the nos terminator from Agrobacterium tumefaciens) were ligated into the binary vector pMOG23 cut with HindIII, resulting in the binary plasmid pMOG450 (see Figure 5).

#### Example 7

##### Transformation of tomato

Tomato (Lycopersicon esculentum cv. Moneymaker) was transformed with the Agrobacterium strain LBA4404 (pMOG228). The basic culture medium consisted of MS-medium (Murashige & Skoog, 1962), supplemented with 30 g/L sucrose, B5 vitamins (Gamborg, 1970), 2 mg/L zeatin riboside and 0.1 mg/L indole acetic (IAA). The media were solidified where necessary with 0.7 g/L Daichin agar.

Cotyledons of six day old, axenically grown seedlings were cut on both ends and pre-incubated for 24 hours on solid medium with a feeder of a 10 day old Petunia cell suspension. The cotyledons were subsequently co-cultivated for 20 hours with a log-phase culture of Agrobacterium tumefaciens strain LBA4404 (pMOG228) which was washed with MS-medium. The cotyledons were dried briefly on sterile filter paper and placed on solid medium with a feeder layer of a 10 day old

Petunia cell suspension. After 48 hours, the cotyledons were transferred to plates containing the same medium without the feeder layer and with 200 mg/L cefotaxim and 100 mg/L vancomycin. Five days after co-cultivation, the cotyledons  
5 were transferred to the same medium plus 100 mg/L kanamycin. The cotyledons were transferred to fresh plates every three weeks.

Shoots were excised and placed on rooting medium (MS-medium supplemented with 10 g/L sucrose, 100 mg/L cefotaxim  
10 and 50 mg/L vancomycin). After rooting, the plants were transferred to the soil and subsequently tested for  $\alpha$ -amylase expression.

#### Example 8

#### 15 Expression of $\alpha$ -amylase from *Bacillus licheniformis* in tomato and carbohydrate analysis of the transgenic fruit

Transgenic tomato plants obtained from the transformation with the constitutive expression construct pMOG228 did not show phenotypic effects. Leaves of the transgenic tomato  
20 plants grown for three weeks in soil were assayed for  $\alpha$ -amylase activity as described in Example 4. Expression levels of  $\alpha$ -amylase in the plants analyzed varied between 0 and 1.2 U/ $\mu$ g soluble protein. The presence of the enzyme was confirmed with Western blotting using antibodies raised  
25 against *Bacillus licheniformis*  $\alpha$ -amylase.

The starch content in leaves obtained from plants grown for 3 weeks in soil and collected half-way through the photoperiod was determined as described in Example 5. Transgenic plants expressing  $\alpha$ -amylase contained demonstrably  
30 less starch in their leaves than control plants.

#### Example 9

#### Cloning of a cDNA encoding mature glucoamylase from *Aspergillus niger*

35 All transformations in *E.coli* in this example were performed in strain DH5 $\alpha$ .

#### a. Isolation of poly A<sup>+</sup> RNA from *Aspergillus niger*

About  $1 \times 10^8$  spores of *Aspergillus niger* strain DS 2975

(deposited at the Centraal Bureau voor Schimmelcultures on August 10, 1988, under number CBS 513.88) are inoculated in 100 ml pre-culture medium containing (per liter): 1 g  $\text{KH}_2\text{PO}_4$ ; 30 g maltose; 5 g yeast-extract; 10 g casein-hydrolysate; 0.5 g  $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$  and 3 g Tween 80. The pH is adjusted to 5.5.

After growing overnight at 34 °C in a rotary shaker, 1 ml of the growing culture is inoculated in a 100 ml main-culture containing (per liter): 2 g  $\text{KH}_2\text{PO}_4$ ; 70 g malto-dextrin (Maldex  $\text{MDO}_3$ , Amylum); 12.5 g yeast-extract; 25 g casein-hydrolysate; 2 g  $\text{K}_2\text{SO}_4$ ; 0.5 g  $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$ ; 0.03 g  $\text{ZnCl}_2$ ; 0.02 g  $\text{CaCl}_2$ ; 0.05 g  $\text{MnSO}_4 \cdot 4 \text{H}_2\text{O}$  and  $\text{FeSO}_4$ . The pH is adjusted to 5.6. The mycelium is grown for 140 hours and harvested. 0.5 g of dry mycelium is frozen with liquid nitrogen and ground. The material is subsequently homogenized with an Ultra turrax (full speed, 1 minute) at 0°C in 10 ml 3 M LiCl, 6 M Urea and maintained overnight at 4°C as described by Auffray and Rougeon (1980). Total cellular RNA is obtained after centrifugation at 16,000 g and dissolved in 3 ml 10 mM Tris-HCl (pH 7.4), 0.5% SDS and extracting twice with phenol:chloroform:isoamylalcohol (50:48:2). The RNA is precipitated with ethanol and redissolved in 1 ml 10 mM Tris-HCl (pH 7.4), 0.5% SDS. For poly A<sup>+</sup> selection, the total RNA sample is heated for 5 minutes at 65°C, adjusted to 0.5 M NaCl and subsequently applied to an oligo(dT)-cellulose column. After several washes with a solution containing 10 mM Tris pH 7.0, 0.5% SDS and 0.1 mM NaCl, the poly A<sup>+</sup> RNA is collected by elution with 10 mM Tris pH 7.0 and 0.5% SDS.

b. Preparation and cloning of a cDNA encoding glucoamylase

To synthesize the first strand of the cDNA, 5 µg of poly A<sup>+</sup> RNA, isolated according to Example 11a, is dissolved in 16.5 µl  $\text{H}_2\text{O}$  and the following components are added: 2.5 µl RNasin (30 U/µl), 10 µl of a buffer containing 50 mM Tris, 6 mM  $\text{MgCl}_2$  and 40 mM KCl, 2 µl 1 M KCl, 5 µl 0.1 M DTT, 0.5 µl oligo(dT)<sub>12-18</sub> (2.5 mg/ml), 5 µl 8 mM dNTP-mix, 5 µl BSA (1 mg/ml) and 2.5 µl Moloney MLV reverse transcriptase (200 U/µl). The mixture is incubated for 30 minutes at 37° C and the reaction is stopped by adding 10 µl 0.2 M EDTA and 50 µl  $\text{H}_2\text{O}$ . An extraction is performed using 110 µl chloroform and

following centrifugation for 5 minutes, the aqueous layer is collected and 110  $\mu$ l 5 M  $\text{NH}_4\text{Ac}$  and 440  $\mu$ l absolute ethanol (temperature:  $-20^\circ\text{C}$ ) are added. Precipitation is performed in a dry ice/ethanol solution for 30 minutes. Following 5 centrifugation for 10 minutes at  $0^\circ\text{C}$ , the cDNA/mRNA pellet is washed with 70% ice-cold ethanol. The pellet is dried and dissolved in 20  $\mu$ l of  $\text{H}_2\text{O}$ .

Isolation of a cDNA encoding glucoamylase is performed with the Polymerase Chain Reaction. Two oligonucleotides are 10 synthesized, based on the nucleotide sequence of glucoamylase G1 cDNA published by Boel *et al.* (1984).

Oligo 1 : 5' CTTCCACCATGGCGACCTTGGATTC 3'

Oligo 2 : 5' AGCTCGAGCTCACCGCCAGGTGTC 3'

With these two oligonucleotides, the region encoding the 15 mature enzyme, i.e. without secretory signal peptide and pro-peptide, preceded by a translation initiation ATG codon (underlined) and flanked by suitable cloning sites is amplified. The obtained DNA is digested with NcoI and SstI. Together with the SstI/HindIII-fragment of p35SGUSINT 20 (Vancanneyt *et al.*, 1990) containing the terminator transcript fragment of the CaMV 35S, the NcoI/SstI fragment is cloned in a three-way ligation into pMOG18 (see Example 2), which is digested with NcoI and HindIII, resulting in plasmid pMOG567.

25 The PstI/SstI-fragment of pMOG567 is subsequently cloned in pIC20H (Marsh *et al.*, 1984), digested with PstI and SstI. In the resulting plasmid, the PstI/HindIII-fragment is replaced by the corresponding amyloglucosidase cDNA-fragment, resulting in pMOG568. The sequence of the HindIII/SstI 30 fragment is compared to the sequence published by Boel *et al.* (1984). The PstI/SstI-fragment of pMOG568 is ligated to the PstI/StyI-fragment of the amyloglucosidase cDNA, and the resulting fragment is cloned in a three-way ligation, together with a synthetic adaptor:

35 5' CATGGCGAC 3'  
3' CGCTGGAAC 5'

into pMOG567 digested with NcoI and SstI, resulting in plasmid pMOG569 which encodes mature amyloglucosidase under control of the CaMV 35S promoter and terminator.

09003047.010563

Example 10Cloning of both  $\alpha$ -amylase from *Bacillus licheniformis* and  
glucoamylase from *Aspergillus niger*

5 All transformations in this example are performed in *E. coli* strain DH5 $\alpha$ .

The HindIII/NcoI class-I patatin promoter fragment (see Example 6) from plasmid pMOG546 is cloned, together with the NcoI/HindIII fragment of plasmid pMOG567 encoding mature  
10 amyloglucosidase from *Aspergillus niger* and the CaMV 35S terminator fragment (see Example 11), into pIC19R (Marsh *et al.*, 1984) linearized with HindIII, resulting in plasmid pMOG440.

Plasmid pMOG450 (see Example 6) is digested with HindIII.  
15 The HindIII fragment, containing the class-I patatin promoter, the DNA fragment encoding mature  $\alpha$ -amylase from *Bacillus licheniformis* and the nos terminator from *Agrobacterium tumefaciens*, is cloned in the binary vector pMOG23 linearized with HindIII. This results in the binary  
20 vector pMOG436.

Plasmid pMOG440 is digested with EcoRI. The EcoRI fragment, containing the class-I patatin promoter, the cDNA fragment encoding mature glucoamylase from *Aspergillus niger* and the CaMV 35S terminator, is cloned in the binary plasmid  
25 pMOG436, linearized with EcoRI. Using restriction enzyme analysis, transformants are screened for the presence of the two expression cassettes in a tandem orientation. The binary vector with the expression cassettes having this orientation, called pMOG437 (Figure 6) is used for transformation  
30 experiments.

The chimeric  $\alpha$ -amylase gene from *Bacillus licheniformis* and the chimeric glucoamylase gene from *Aspergillus niger*, both under the control of the tuber-specific class-I patatin promoter, as present on the binary plasmid pMOG437, are  
35 mobilized in a triparental mating with the *E. coli* strain HB101 containing plasmid pRK2013 (Ditta *et al.*, 1980) into *Agrobacterium* strain LBA4404 which contains a plasmid having the virulence genes necessary for T-DNA transfer to the plant (Hoekema *et al.*, 1983).

### Example 11

#### Transformation of potato

Potato (Solanum tuberosum cv. Désiree) was transformed  
5 with the Agrobacterium strain LBA4404 (pMOG437) as described  
by Hoekema et al. (1989).

The basic culture medium was a MS30R3-medium, consisting  
of MS-medium (Murashige & Skoog, 1962), supplemented with 30  
g/L sucrose and with R3-vitamins (Ooms et al., 1987) and,  
10 where indicated, 5  $\mu$ M zeatin riboside (ZR) and 0.3  $\mu$ M indole  
acetic acid (IAA). The media were solidified where necessary  
with 0.7 g/L Daichin agar.

Tubers of Solanum tuberosum cv. Désiree were peeled and  
surface-sterilized for 20 minutes in 0.6% hypochlorite  
15 solution containing 0.1% Tween-20. The potatoes were washed  
thoroughly in large volumes of sterile water for at least 2  
hours. Discs of approximately 2 mm thickness were sliced from  
cylinders of tuber tissue prepared with a corkbore. Discs  
were incubated for 20 minutes in a suspension consisting of  
20 the MS30R3-medium without ZR and IAA, containing between  $10^6$ -  
 $10^7$  bacteria/ml of Agrobacterium LBA4404 (pMOG437). The discs  
were subsequently blotted dry on sterile filter paper and  
transferred to solid MS30R3-medium with ZR and IAA. Discs  
were transferred to fresh medium with 100 mg/L cefotaxim and  
25 50 mg/L vancomycin after 2 days. A week later, the discs were  
again transferred to the same medium but this time 100 mg/L  
kanamycin was present to select for transgenic shoots. After  
4-8 weeks, shoots emerged from the discs at a frequency of 5-  
10 shoots per 100 discs. Shoots were excised and placed on  
30 rooting medium (MS30R3-medium without ZR and IAA, but with  
100 mg/L cefotaxim and 100 mg/L kanamycin), and propagated  
axenically by meristem cuttings and transferred to soil. The  
plants were allowed to tuberize and were subsequently tested  
for expression of the genes of interest.

35

### Example 12

Simultaneous tuber-specific expression of both  
 $\alpha$ -amylase (Bacillus licheniformis) and glucoamylase  
(Aspergillus niger) in potato and carbohydrate

analysis of transgenic tubers

Potato plants are transformed with binary vector pMOG437 as described in Example 7. The plants are assayed for both  $\alpha$ -amylase and glucoamylase activity. Alpha-amylase activity is determined as described in Example 4. The presence of glucoamylase is demonstrated by Western blotting, using antibodies raised against Aspergillus niger glucoamylase. Plant material (about 50 mg) is homogenized in 100  $\mu$ l assay buffer and homogenized. The homogenate is spun for 10 minutes in an Eppendorf centrifuge. The supernatant is tested for  $\alpha$ -amylase activity, for the presence of glucoamylase and for protein content. The presence of the enzymes is only detected in the tubers of the transgenic potatoes.

Tubers of transgenic potatoes expressing both enzymes are analyzed for the presence of soluble sugars by HPLC. A higher content of soluble sugars is found in transgenic tubers as compared to control plants.

09003047.040598

Index of Cited References

- Auffray, C. & Rougeon, F. (1980) *Eur. J. Biochem.* 107, 303.
- Baulcombe, D.C., Saunders, G.R., Bevan, M.W., Mayo, M.A. & Harrison, B.D. (1986) *Nature* 321, 446.
- 5 Bevan, M. (1984) *Nucl. Acids Res.* 12, 8711.
- Bevan, M., Barker, R., Goldsbrough, A., Jarvis, M., Kavanagh, T. & Iturriaga (1986) *Nucl. Acids Res.* 14, 4625.
- Bhattacharyya, M., Smith, A.M., Ellis, T.H.N., Hedley, C. & Martin, C. (1990) *Cell* 60, 115
- 10 Bird, C.R., Smith, C.J.S., Ray, J.A., Moureau, P., Bevan, M.W., Bird, A.S., Hughes, S., Morris, P.C., Grierson, D. & Schuch, W. (1988) *Plant Mol. Biol.* 11, 651.
- Boel, E., Hjort, I., Svensson, B., Norris, F., Norris, K.E. & Fiil, N.P. (1984) *EMBO J.*, 3, 1097-1102.
- 15 Brederode, F.T., Koper-Zwarthoff, E.C. & Bol, J.F. (1980) *Nucl. Acids Res.* 8, 2213.
- Caspar, T., Huber, S.C. & Somerville, C. (1985) *Plant Physiol.* 79, 11.
- 20 Caspar, T., Lin, T.-P., Monroe, J., Bernhard, W., Spilatro, S., Preiss, J. & Somerville, C. (1989) *Proc. Natl. Acad. Sci. USA* 86, 5830.
- Coruzzi, G., Broglie, R., Edwards, C., Chua, N.-H. (1984) *EMBO J.* 3, 1671-1679.
- 25 Ditta, G., Stanfield, S., Corbin, D. & Helinski, D.R. (1980) *Proc. Natl. Acad. Sci. USA*, 77, 7347.
- Fraley, R.T., Rogers, S.G., Horsch, R.B. (1986) *CRC Critical Reviews In Plant Sciences* 4, 1-46.
- Gamborg, O.L. (1970) *Plant Physiol.*, 45, 372.
- 30 Gordon-Kamm, W.J., Spencer, T.M., Mangano, M.L., Adams, T.R., Daines, R.J., Start, W.G., O'Brien, J.V., Chambers, S.A., Adams Jr., W.R., Willets, N.G., Rice, T.B., Mackey, C.J., Krueger, R.W., Kausch, A.P. & Lemaux, P.G. (1990) *The Plant Cell* 2, 603.
- 35 Guilley, H., Dudley, R.K., Jonard, J., Balazs, E. & Richards, K.E. (1982) *Cell* 30, 763.
- Hanson, H.R. & McHale, N.A. (1988) *Plant Physiol.* 88, 838.
- Hoekema, A., Hirsch, P.R., Hooykaas, P.J.J. & Schilperoort, R.A. (1983) *Nature* 303, 179.

09003047 0 10598



- Hoekema, A., Huisman, M.J., Molendijk, L., Van den Elzen, P.J.M. & Cornelissen, B.J.C. (1989) *Bio/Technology* 7, 273.
- Horsch, R.B., Fry, J.E., Hoffmann, N.L., Eichholtz, D., Rogers & S.G. & Fraley, R.T. (1985) *Science* 227, 1229.
- 5 Hovenkamp-Hermelink, J.H.M., Jacobsen, E., Ponstein, A.S., Visser, R.G.F., Vos-Scheperkeuter, G.H., Bijmolt, E.W., De Vries, J.N., Witholt, B. & Feenstra, W.J. (1987) *Theor. Appl. Genet.*, 75, 217.
- 10 Jefferson, R.A. (1987) *Plant Mol. Biol. Rep.* 5, 387.
- Kay, R., Chan, A., Dayly, M. & McPherson, J. (1987) *Science* 236, 1299.
- Lacks, S.A. & Springhorn, S.S. (1980) *J. Biol. Chem.* 255, 7467.
- 15 Lee, B., Murdoch, K., Topping, J., Kreis, M. & Jones, M.G.K. (1989) *Plant Mol. Biol.* 13, 21.
- Lin, T-P., Spilatro, S.R. & Preiss, J. (1988a) *Plant Physiol.* 86, 251.
- Lin, T-P., Caspar, T., Somerville, C. & Preiss, J. (1988b) *Plant Physiol.* 86, 1131.
- 20 Lin, T-P., Caspar, T., Somerville, C. & Preiss, J. (1988c) *Plant Physiol.* 88, 1175.
- Marsh, J.L., Erfle, M. & Wykes, E.J. (1984) *Gene* 32, 481.
- Mettler, I.J. (1987) *Plant Mol. Biol. Rep.* 5, 346.
- 25 Mignery, G.A., Pikaard, C.S. & Park, W.D. (1988) *Gene*, 62, 27.
- Murashige, T. & Skoog, F. (1962) *Physiol. Plant.* 14, 473.
- Okita, T.W., Greenberg, E., Kuhn, D.N. & Preiss, J. (1979) *Plant Physiol.* 64, 187.
- 30 Ooms, G., Burrell, M.M., Karp, A., Bevan, M. & Hille, J. (1987) *Theor. Appl. Genet.* 73, 744.
- Potrykus, I. (1990) *Bio/Technol.* 8, 535.
- Rocha-Sosa, M., Sonnewald, U., Frommer, W.B., Stratman, M., Schell, J., & Willmitzer, L. (1989) *EMBO J.* 8, 23.
- 35 Ryan, A.J., Royal, C.L., Hutchinson, J. & Shaw, C.H. (1989) *Nucl. Acids Res.* 17, 3584.
- Saito, N. (1973) *Arch. Biochem. Biophys.* 155, 290.
- Schreier, P.H., Seftor, E.A., Schell, J., and Bohnert, H.J. (1985) *EMBO J.* 4, 25-32.

09003047-010598

- Schilperoort, R.A., Hoekema, A. & Hooykaas, P.J.J. (1984)  
European Patent Application No. EP-A 0 120 516.
- Shimamoto, K., Terada, R., Izawa, T. & Fujimoto, H. (1989)  
Nature 338, 274.
- 5 Sijmons, P.C., Dekker, B.M.M., Schrammeijer, B., Verwoerd,  
T.C., Van Den Elzen, P.J.M. & Hoekema, A. (1990)  
Bio/Technology 8, 217.
- Shannon, J.C. & Garwood, D.L. (1984) In: Starch. Chemistry  
and technology. p. 25. (Whistler, R.L. et al., eds.).  
10 Academic Press Inc., Orlando.
- Smeekeens, S., Weisbeek, P., Robinson, C. (1990) T.I.B.S. 15,  
p.73.
- Tague, B.W. & Chrispeels, M.J. (1988) Plant Phys. 86, 506.
- Tingey, S.V., Walker, E.L. & Coruzzi, G.M. (1987) EMBO J. 6,  
15 3565-3669.
- Vancanneyt, G., Schmidt, R., O'Connor-Sanchez, A.,  
Willmitzer, L. & Rocha-Sosa, M. (1990) Mol. Gen. Genet.,  
220, 245.
- Van den Broeck, G., Timko, M.P., Kausch, A.P., Cashmore,  
20 A.R., Van Montagu, M., Herrera-Estrella, L. (1985) Nature  
313, 358-363.
- Vasil, V., Redway, F. & Vasil, I.K. (1990) Bio/Technol. 8,  
429.
- Vasil, V., Brown, S.M., Re, D., Fromm, M.E., and Vasil, I.K.  
25 (1991) Bio/Technol., 9, 743.
- Wenzler, H.-C., Miguery, G.A., Fisher, L.H. & Park, W.D.  
(1989) Plant Mol. Biol. 12, 41.

09003047-40595

Claims

1. A method for modifying the carbohydrate composition of a plant or plant organ characterized by the growing of a transgenic plant containing an expression cassette which contains a DNA sequence encoding a (primary) enzyme of interest capable of degrading a plant polysaccharide, under conditions conducive whereby said enzyme-encoding DNA sequence is expressed and the carbohydrate composition of said plant or plant organ is modified, with the proviso that if said plant or plant organ is potato, the DNA sequence encoding said (primary) enzyme of interest originates from a microbial source.
2. The method of claim 1 further characterized in that said expression cassette contains a regulatory sequence capable of directing the expression of said enzyme of interest at a selected maturity stage of the development of the transgenic plant or plant organ.
3. The method of claim 1 further characterized in that said expression construct is capable of directing the tissue-specific expression of said enzyme of interest.
4. The method of claim 1 further characterized in that the DNA sequence encoding said (primary) enzyme of interest is provided with a leader sequence capable of targeting the expressed enzyme to a pre-determined cellular compartment or organelle.
5. The method of claim 1 further characterized in that an increase in the content of soluble saccharides containing up to six monosaccharide units is obtained in said transgenic plant or plant organ as a result of the action of said enzyme of interest.
6. The method of claim 1 wherein said (primary) enzyme of interest is selected from the group selected from amylases, glucanases, cellulases, endoglucanases, arabinanases,

galactanases, mannanases, xylanases, fucosidases, rhamnosidases, levanase and inulanase.

7. The method of claim 1 wherein the DNA sequence encoding  
5 said (primary) enzyme of interest originates from a microbial source.

8. The method of claim 7 wherein the DNA sequence encoding  
10 said (primary) enzyme of interest is selected from the group consisting of an  $\alpha$ -amylase originating from Bacillus licheniformis and a glucoamylase originating from Aspergillus niger.

9. The method according to claim 1 further characterized in  
15 that said transgenic plant contains one or more expression constructs containing DNA constructs encoding a secondary enzyme of interest other than and in addition to said (primary) enzyme of interest, said secondary enzyme of interest being capable of using the starch degradation  
20 products resulting from the action of said primary enzyme of interest as a substrate.

10. The method of claim 9 further characterized in that said  
25 additional enzyme of interest is selected from the group consisting of glucoamylases, pullulanases, isoamylases, cyclomaltodextrin-D-glucotransferases,  $\alpha$ -(1-4)-glucanases,  $\alpha$ -(1-4)-glucosidases,  $\alpha$ -(1-6)-glucosidases,  $\beta$ -glucosidases, D-glucoseisomerases and inulinases.

30 11. The method of any one of claims 1 - 10 further characterized in that said transgenic plant is selected from the group consisting of tomato, potato, corn, cassave, carrot, lettuce, strawberry and tobacco.

35 12. An expression construct characterized in that a DNA sequence encoding an enzyme of interest capable of degrading a plant polysaccharide is operably linked to a regulatory sequence capable of directing the expression of said enzyme of interest at a selected maturity stage of the development

09003047-010543

of a transgenic plant or plant organ.

13. An expression construct characterized in that a DNA sequence encoding an enzyme of interest capable of degrading  
5 a plant polysaccharide is operably linked to the 35S CaMV promoter.

14. An expression construct characterized in that a DNA sequence encoding an enzyme of interest capable of degrading  
10 a plant polysaccharide is operably linked to a regulatory sequence capable of directing the tissue-specific expression of said enzyme of interest.

15. A vector comprising an expression construct according to  
15 any of the claims 12 - 14.

16. A transgenic plant characterized in that said plant contains an expression cassette according to any one of  
claims 12 - 14.

20 17. A bacterial strain characterized in that said bacterial strain contains a vector according to claim 15.

18. A transgenic plant or plant organ characterized in that  
25 said plant or plant organ contains a modified carbohydrate composition a result of the method according to either one of claims 1 and 9.

865070 "4050060

ABSTRACT OF THE DISCLOSURE

The present invention provides plants with a modified taste, solids content and/or texture. The invention also provides methods of obtaining such plants via transformation with DNA constructs containing genes encoding enzymes capable of degrading plant polysaccharides and optionally additional genes encoding enzymes which are capable of further modifying the degradation products resulting from the first degradation step.

5

05003047 010593  
265010 40E060




FIGURE 1

XbaI

\*

TCTAGAGTC ATGAACAAC AAAAACGGCT TTAAGCCCGA TTGCTGACGC TGTTATTTCG

PstI HgaI

GCTCATCTTC TTGCTGCCTC ATTCTGCAGC AGCGGGGCA AATCTTAATG GGACGCTGAT

GCAGTATTTT GAAATGGTACA TGCCCAATGA CGGCCAACAT TGGAAAGCGTT TGC AAAACGA

CTCGGCATAT TTGGCTGAAC ACGGTATTAC TGCCGCTCTGG ATTCCCCCGG CATATAAGGG

AACGAGCCAA GCGGATGTGG GCTACGGTGC TTACGACCTT TATGATTTAG GGGAGTTTCA

TCAAAAAGGG ACGGTTCCGA CAAGAATACGG CACAAAAGGA GAGCTGCAAT CTGCGATCAA

AAGTCTTCAT TCCCGCGACA TTAAAGTTTA CGGGGATGTG GTCATCAACC ACAAAGGCGG

CGCTGATCG ACCGAAAGATG TAACCGCGGT TGAAGTCGAT CCCGCTGACC GCAACCGCGT

AATTTCAGGA GAACACCTAA TTAAAGCCCTG GACACATTTT CATTTTCCGG GCGCGGCGAG

CACATACAGC GATTTTAAAT GG CATTTGTA CCATTTTGAC GGAACCGATT GGGACGAGTC

CCGAAAGCTG AACCGCATCT ATAAAGTTTCA AGGAAAGGCT TGGGATTGGG AAGTTTCCAA

TGAAAACGGC AACTATGATT ATTGTATGTA TGCCGACATC GATTATGACC ATCCTGATGT

CGCAGCAGAA ATTAAGAGAT GGGGCACCTG GTATGCCAAT GAACTGCAAT TGGACGGTTT

CCGTCTTGAT GCTGTCAAAC ACATTAAAT TTCTTTTTTG CGGGATTGGG TTAATCATGT

CAGGGA AAA ACGGGAAGG AAATGTTTAC GGTAGCTGAA TATTGGCAGA ATGACTTGGG



SEQUENCE "CHOE 0060"  
 FIGURE 2 (Sheet 2 of 2)

CGCGCTGGAA AACTATTGA ACAAACAAA TTTTAATCAT TCAGTGTTG ACGTGCCGCT  
 TCATTATCAG TTCCATGCTG CATCGACACA GGGAGGCGG TATGATATGA GGAAATTGCT  
 GAACGGTACG GTCGTTTCCA AGCATCCGTT GAAATCGGTT ACATTGTGCG ATAACCATGA  
 TACACAGCCG GGGCAATCGC TTGAGTCGAC TGTCCAAACA TGGTTAAGC CGCTTGCTTA  
 CGCTTTTATT CTCACAAGGG AATCTGGATA CCTCAGGTT TTCTACGGG ATATGTACGG  
 GACGAAAGGA GACTCCACG GCGAATTCC TGCTTGAAA CACAAAATTG AACCGATCTT  
 AAAAGCGAGA AAACAGTATG CGTACGGAGC ACAGCATGAT TATTTCGACC ACCATGACAT  
 TGTCGGCTGG ACAAGGGAAG GCGACAGCTC GGTGCAAT TCAGGTTGG CGGCATTAAT  
 AACAGACGGA CCGGGTGGG CAAAGCGAAT GTATGTCGGC CGGCAAAACG CCGGTGAGAC  
 ATGGCATGAC ATTACCGGAA ACCGTTCGGA GCCGTTGTC ATCAATTGCG AAGGCTGGG  
 AGAGTTTCAC GTAAACGGCG GGTGCTTTC AATTATGTT CAAAGATAGA AGAGCAGAGA  
BamHI  
 GGACGGATTT CCTGAAGGAA ATCCGTTTTT TTATTTTGGC CGTCTTATAA ATTTCTTTGA  
 TTACATTTTA TAATTAATTT TAACAAAGTG TCATCAGCCC TCAGGAAGGA CTGCTGACA  
 GTTTGAATCG CATAGGTAAG GCGGGGATGA AATGGCAACG TTATCTGATG TAGCAAAGAA  
BclI  
 AGCAAATGTG TCGAAAATGA CCGTATCCGG GGTGATCA

255070 " 44000050

FIGURE 3

oligonucleotide duplex A

		<u>NcoI</u>	<u>BamHI</u>	<u>HindIII</u>	
		┌	┌	┌	
5'	GGGTTT	TTA	TTT	TAAT	TTCTTTCAAA
3'	CCCAAAA	AT	AAAA	AGAA	TTTATGAAGGTGGTACCCATTGCCTAGGTTCCA

oligonucleotide duplex B

		<u>NcoI</u>		<u>HgaI</u>	SITE
		┌			α-AMYLASE
5'	CATG				GCAAATCTTAATGGACGCTGATG
3'					CGTTAGAATTACCTGCGACTACGTCAT

Met' mature α-Amylase




FIGURE 4




FIGURE 5




FIGURE 6

<b>COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY</b> (Includes Reference to PCT International Applications)	<b>ATTORNEY'S DOCKET NUMBER</b> 261922003301		
<p>As a below named inventor I hereby declare that:</p> <p>My residence, post office address and citizenship are as stated below next to my name,</p> <p>I believe I (am-) the original, first and sole inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled:</p> <p style="text-align: center;"><b>TRANSGENIC PLANTS HAVING A MODIFIED CARBOHYDRATE CONTENT</b></p> <p>the specification of which (check only one item below):</p> <p style="margin-left: 40px;"><input checked="" type="checkbox"/> was filed as PCT international application</p> <p style="margin-left: 80px;">Number <b>PCT/NL91/00171</b> on 13 September 1991, and was amended under PCT Article 19 on (if applicable).</p> <p>I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.</p> <p>I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37 Code of Federal Regulations § 1.56(a) and (b).</p> <p>I hereby claim foreign priority benefits under Title 35 United States Code § 119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:</p>			
<b>PRIOR FOREIGN/PCT APPLICATION(S) AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. § 119:</b>			
COUNTRY (if PCT indicate "PCT")	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 35 U.S.C. § 119
EPO	90202434.8	13 September 1990	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO

255070 "440E0060"

<b>Combined Declaration for Patent Application and Power of Attorney (Continued)</b> (Includes Reference to PCT International Applications)	ATTORNEY'S DOCKET NUMBER 261922003301
--	--

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, § 1.56(a) which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:

**PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT UNDER 35 U.S.C. § 120:**

U.S. APPLICATIONS		STATUS (Check one)		
U S APPLICATION NUMBER	U S FILING DATE	PATENTED	PENDING	ABANDONED

PCT APPLICATIONS DESIGNATING THE U.S.			STATUS (Check one)		
PCT APPLICATION NUMBER	PCT FILING DATE	U S SERIAL NUMBERS ASSIGNED (if any)	PATENTED	PENDING	ABANDONED
PCT/NL91/00171	13 September 1991				

**POWER OF ATTORNEY:** As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (List name and registration number)

Thomas E. Ciotti (Reg No. 21,013), Kate H. Murashige (Reg No. 29,959), Gladys H. Monroy (Reg No. 32,430), Debra A. Shetka (Reg No. 33,309), Paul Schenck (Reg No. 27,253), E. Thomas Wheelock (Reg No. 28,825), Freddie K. Park (Reg No. 35,636), Susan K. Lehnhardt (Reg No. 33,943), Shmuel Livnat (Reg No. 33,949), Tyler Dylan (Reg No. 37,612), Antoinette F. Konski (Reg No. 34,202), Harry J. Macey (Reg No. 32,818), Stuart P. Kaler (Reg No. 35,913), David L. Bradfute (Reg No. 39,117), Robert Saltzberg (Reg No. 36,910), Laurie A. Axford (Reg No. 35,053), Mani Adeli (Reg No. 39,585), Catherine M. Polizzi (Reg No. 40,130), Sean Brennan (Reg No. 39,917), J. Michael Schiff (Reg No. 40,253), Robert A. Millman (Reg No. 36,217), Robert K. Cerpa (Reg No. 39,933), Ronald D. Devore (Reg No. 39,958), Lee K. Tan (Reg No. 39,447), Alan W. Cannon (Reg No. 34,977), Madeline I. Johnston (Reg No. 36,174), Dahna S. Pasternak (Reg No. P-41,411), Stephen C. Durant (Reg No. 31,506), Frank Wu (Reg No. P-41,386), Hector Gallegos (Reg No. P-40,614), Barry E. Bretschneider (Reg No. 28,055), Charles D. Holland (Reg No. 35,196)

<b>Send correspondence to:</b> Kate H. Murashige Morrison & Foerster LLP 2000 Pennsylvania Avenue, N.W. Washington, D.C. 20006-1888	<b>Direct telephone calls to:</b> Kate H. Murashige at 202 887 1533
---	---

201	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE & ZIP CODE/COUNTRY
202	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE & ZIP CODE/COUNTRY
203	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE & ZIP CODE/COUNTRY

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.



SIGNATURE OF INVENTOR 201 <i>Albert van Ooyen</i>	SIGNATURE OF INVENTOR 202 <i>Krijn Rietveld</i>	SIGNATURE OF INVENTOR 203 <i>Jan van Galenlaan</i>
DATE Aug. 25, 1997	DATE Sept 29, 1997	DATE Aug 27, 1997

ADDITIONAL PAGE OF INVENTORS

<b>Combined Declaration for Patent Application and Power of Attorney (Continued)</b> (Includes Reference to PCT International Applications)				ATTORNEY'S DOCKET NUMBER 261922003301	
I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, § 1.56(a) which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:					
<b>PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT UNDER 35 U.S.C. § 120:</b>					
U.S. APPLICATIONS			STATUS (Check one)		
U S APPLICATION NUMBER	U S FILING DATE		PATENTED	PENDING	ABANDONED
PCT APPLICATIONS DESIGNATING THE U.S.			STATUS (Check one)		
PCT APPLICATION NUMBER	PCT FILING DATE	U S SERIAL NUMBERS ASSIGNED (if any)	PATENTED	PENDING	ABANDONED
PCT/NL91/00171	13 September 1991				
<b>POWER OF ATTORNEY:</b> As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (List name and registration number)					
Thomas E. Ciotti (Reg No. 21,013), Kate H. Murashige (Reg No. 29,959), Gladys H. Monroy (Reg No. 32,430), Debra A. Shetka (Reg No. 33,309), Paul Schenck (Reg No. 27,253), E. Thomas Wheelock (Reg No. 28,825), Freddie K. Park (Reg No. 35,636), Susan K. Lehnhardt (Reg No. 33,943), , Shmuel Livnat (Reg No. 33,949), Tyler Dylan (Reg No. 37,612), Antoinette F. Konski (Reg No. 34,202), Harry J. Macey (Reg No. 32,818), Stuart P. Kaler (Reg No. 35,913), David L. Bradfute (Reg No. 39,117), Robert Saltzberg (Reg No. 36,910), Laurie A. Axford (Reg No. 35,053), Mani Adeli (Reg No. 39,585), Catherine M. Polizzi (Reg No. 40,130), Sean Brennan (Reg No. 39,917), J. Michael Schiff (Reg No. 40,253), Robert A. Millman (Reg No. 36,217), Robert K. Cerpa (Reg No. 39,933), Ronald D. Devore (Reg No. 39,958), Lee K. Tan (Reg No. 39,447), Alan W. Cannon (Reg No. 34,977), Madeline I. Johnston (Reg No. 36,174), Dahna S. Pasternak (Reg No. P-41,411), Stephen C. Durant (Reg No. 31,506), Frank Wu (Reg No. P-41,386), Hector Gallegos (Reg No. P-40,614), Barry E. Bretschneider (Reg No. 28,055), Charles D. Holland (Reg No. 35,196)					
<b>Send correspondence to:</b> Kate H. Murashige Morrison & Foerster LLP 2000 Pennsylvania Avenue, N.W. Washington, D.C. 20006-1888			<b>Direct telephone calls to:</b> Kate H. Murashige at 202 887 1533		
201	FULL NAME OF INVENTOR	FAMILY NAME VAN DEN ELZEN	FIRST GIVEN NAME Petrus	SECOND GIVEN NAME Josephus Maria	
	RESIDENCE & CITIZENSHIP	CITY Voorhout	STATE OR FOREIGN COUNTRY Netherlands	COUNTRY OF CITIZENSHIP Netherlands	
	POST OFFICE ADDRESS	POST OFFICE ADDRESS Cayennehof 26	CITY 2215 BH Voorhout	STATE & ZIP CODE/COUNTRY Netherlands	
202	FULL NAME OF INVENTOR	FAMILY NAME PEN	FIRST GIVEN NAME Jan	SECOND GIVEN NAME	
	RESIDENCE & CITIZENSHIP	CITY Leiden	STATE OR FOREIGN COUNTRY Netherlands	COUNTRY OF CITIZENSHIP Netherlands	
	POST OFFICE ADDRESS	POST OFFICE ADDRESS Voszegge 9	CITY 2318 ZJ Leiden	STATE & ZIP CODE/COUNTRY Netherlands	
203	FULL NAME OF INVENTOR	FAMILY NAME HOEKEMA	FIRST GIVEN NAME Andreas	SECOND GIVEN NAME	
	RESIDENCE & CITIZENSHIP	CITY Oegstgeest	STATE OR FOREIGN COUNTRY Netherlands	COUNTRY OF CITIZENSHIP Netherlands	
	POST OFFICE ADDRESS	POST OFFICE ADDRESS Warmonderweg 66	CITY 2341 JX Oegstgeest	STATE & ZIP CODE/COUNTRY Netherlands	
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.					
SIGNATURE OF INVENTOR 201 <i>Peter van den Elzen</i>		SIGNATURE OF INVENTOR 202 <i>Jan Pen</i>		SIGNATURE OF INVENTOR 203 <i>Andreas Hoekema</i>	
DATE <i>9/12/97</i>		DATE <i>8/19/97</i>		DATE <i>8/22/97</i>	



ADDITIONAL PAGE OF INVENTORS

<b>Combined Declaration for Patent Application and Power of Attorney (Continued)</b> (Includes Reference to PCT International Applications)				ATTORNEY'S DOCKET NUMBER 261922003301	
I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, § 1.56(a) which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:					
<b>PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT UNDER 35 U.S.C. § 120:</b>					
U.S. APPLICATIONS			STATUS (Check one)		
U S APPLICATION NUMBER	U S FILING DATE		PATENTED	PENDING	ABANDONED
PCT APPLICATIONS DESIGNATING THE U.S.			STATUS (Check one)		
PCT APPLICATION NUMBER	PCT FILING DATE	U S SERIAL NUMBERS ASSIGNED (if any)	PATENTED	PENDING	ABANDONED
PCT/NL91/00171	13 September 1991				
<b>POWER OF ATTORNEY:</b> As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (List name and registration number)					
Thomas E. Ciotti (Reg No. 21,013), Kate H. Murashige (Reg No. 29,959), Gladys H. Monroy (Reg No. 32,430), Debra A. Shetka (Reg No. 33,309), Paul Schenck (Reg No. 27,253), E. Thomas Wheelock (Reg No. 28,825), Freddie K. Park (Reg No. 35,636), Susan K. Lehnhardt (Reg No. 33,943), Shmuel Livnat (Reg No. 33,949), Tyler Dylan (Reg No. 37,612), Antoinette F. Konski (Reg No. 34,202), Harry J. Macey (Reg No. 32,818), Stuart P. Kaler (Reg No. 35,913), David L. Bradfute (Reg No. 39,117), Robert Saltzberg (Reg No. 36,910), Laurie A. Axford (Reg No. 35,053), Mani Adeli (Reg No. 39,585), Catherine M. Polizzi (Reg No. 40,130), Sean Brennan (Reg No. 39,917), J. Michael Schiff (Reg No. 40,253), Robert A. Millman (Reg No. 36,217), Robert K. Cerpa (Reg No. 39,933), Ronald D. Devore (Reg No. 39,958), Lee K. Tan (Reg No. 39,447), Alan W. Cannon (Reg No. 34,977), Madeline I. Johnston (Reg No. 36,174), Dahna S. Pasternak (Reg No. P-41,411), Stephen C. Durant (Reg No. 31,506), Frank Wu (Reg No. P-41,386), Hector Gallegos (Reg No. P-40,614), Barry E. Bretschneider (Reg No. 28,055), Charles D. Holland (Reg No. 35,196)					
<b>Send correspondence to:</b> Kate H. Murashige Morrison & Foerster LLP 2000 Pennsylvania Avenue, N.W. Washington, D.C. 20006-1888			<b>Direct telephone calls to:</b> Kate H. Murashige at 202 887 1533		
201	FULL NAME OF INVENTOR	FAMILY NAME SIMONS	FIRST GIVEN NAME Peter	SECOND GIVEN NAME Christiaan	
	RESIDENCE & CITIZENSHIP	CITY Amsterdam	STATE OR FOREIGN COUNTRY Netherlands	COUNTRY OF CITIZENSHIP Netherlands	
	POST OFFICE ADDRESS	POST OFFICE ADDRESS Valeriusstraat 210-3	CITY 1075 GK Amsterdam	STATE & ZIP CODE/COUNTRY Netherlands	
202	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE & ZIP CODE/COUNTRY	
203	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE & ZIP CODE/COUNTRY	
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.					
SIGNATURE OF INVENTOR 201 		SIGNATURE OF INVENTOR 202 		SIGNATURE OF INVENTOR 203	
DATE 7/1/17		DATE		DATE	